Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis

E. Randall Lanier, Scott Foster, Tom Brundage, Sunwen Chou, Mark N. Prichard, Steven Kleiboeker, Chad Wilson, Donella Colville, Herve Mommeja-Marin

Research output: Contribution to journalArticle

7 Scopus citations


Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the clinical resistance profile for brincidofovir. In this study, no known resistance-associated mutations were detected in brincidofovir-treated subjects; identified genotypic substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that these changes represent polymorphisms unrelated to brincidofovir resistance. Lack of evidence for genotypic resistance during prophylaxis suggests that first-line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream options for patients.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalJournal of Infectious Diseases
Issue number1
Publication statusPublished - Jul 1 2016



  • Brincidofovir
  • CMV
  • CMV (DNA) polymerase
  • CMV phosphotransferase
  • cytomegalovirus
  • stem cell transplantation
  • UL54
  • UL97

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this